Ovarian and prostate cancers.

Robert Klupacs, CEO of Circadian stated that, ‘This data, as well as the data we have publically previously released, continues to build the solid case for medical evaluation of VGX-100 and its possible future use as a new cancer treatment option. We are very excited by the prospect of commencing clinical development later this full 12 months.’ Circadian controls exclusive world-wide rights to an extensive intellectual property portfolio allowing it to commercially develop antibodies targeting VEGF-C..The academy is certainly attempting to attract more females to the specialty by putting advertisements in medical student publications and sponsoring booths at medical pupil meetings. Loyola University Wellness System is helping lead the effort. At Loyola, 20 % of orthopaedic faculty and 16 % of orthopaedic residents are ladies. And at Loyola’s Stritch College of Medication, six of the 11 fourth-year students trying to get orthopaedic residencies are females.